Publications

Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.

Dodero A

Exp Hematol. 33(8):920-7.

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

Ricca I

Leukemia. 19(4):644-51.

High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt’s lymphoma in adults.

Di Nicola M

Br J Haematol. 126(6):815-20.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M

Clin Cancer Res. 10(16):5381-90.

Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone.

Carlo-Stella C

Exp Hematol. 32(2):171-8.

Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene.

Khobta A, Carlo-Stella C, Capranico G

Cancer Res. 64(8):2656-62.

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.

Carlo-Stella C

Blood. 2004 Jan 15;103(9):3287-95.

Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.

Carlo-Stella C

Exp Hematol. 32(1):68-75.

Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.

Di Nicola M

Haematologica. 88(12):1396-404.

Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.

Di Nicola M

Hum Gene Ther. 14(14):1347-60.